Research
TAO Qian
Name : TAO Qian 陶謙
Title : Professor
Home Department :  Clinical Oncology
Email : qtao@cuhk.edu.hk
Phone Number: (852) 3505 1340
Fax Number: (852) 2648 8842
 Other Contacts:   (852) 3505 1126 (Lab)
 Website: http://www.clo.cuhk.edu.hk/eng/prof-qian-tao.asp

Biography:

  • 2008- Present  Professor, Department of Clinical Oncology, The Chinese University of Hong Kong
  • 2004-2008 Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong
  • 1999-2004 Assistant Professor, Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, Baltimore; Cancer Epigenetics Lab, Johns Hopkins Singapore
  • 1995-1999   Postdoct, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
  • 1991-1995   PhD, Department of Pathology, The University of Hong Kong
Professional Societies:
  • 2008-Present    Vice-President, The Epigenetics Society 
  • 1994-Present    International Association for Research on EBV and Associated Diseases
  • American Association for Cancer Research (AACR)


Specialised Research Area(s):

Epigenetics, epigenomics, tumor suppressor gene, CpG methylation, carcinoma, cancer

Selected Publications:

1. L Li, Y Fan, X Huang, J Luo, L Zhong, XS Shu, L Lu, T Xiang, AT Chan, W Yeo, C Chen, WY Chan, RL Huganir, Q Tao. Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. iScience (Cell Press) 2019; 21:1-18

2. Xiang T, Tang J, Li L, Peng W, Du Z, Wang X, Li Q, Xu H, Xiong L, Xu C, Le X, Wei X, Yu F, Li S, Xiao Q, Luo B, Xiang X, Huang A, Lin Y, Ren G, Tao Q. Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis. Theranostics. 2019; 9(26):8182-8195.

3. Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q. Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. Theranostics. 2018; 8(1):61-77.

4. Li L, Li C, Mao H, Du Z, Chan WY, Murray P, Luo B, Chan AT, Mok TS, Chan FK, Ambinder RF, Tao Q. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Scientific Reports. 2016; 6:26591.

5. Li LL, Zhang Y, Fan YC, Sun K, Su XW, Du ZF, Tsao SW, Loh TKS, Sun H, Chan ATC, Zeng YX, Chan WY, Chan FK, Tao Q. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics 2015; 7: 155-173.

6. Wang SY, Cheng YD, Du W, Lu LN, Zhou L, Wang HT, Kang W, Li XX, Tao Q, Sung JJY, Yu J. Zinc-finger protein 545 is a novel tumour suppressor that acts by inhibiting ribosomal rna transcription in gastric cancer. Gut 2013; 62: 833-841. (*corresponding authors)

7. Cheng YD, Geng H, Cheng SH, Liang P, Bai Y, Li JS, Srivastava G, Ng MHL, Fukagawa T, Wu XS, Chan ATC, Tao Q. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Research 2010; 70: 6516-6526.

8. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li HY, Cheng YY, Rocken C, Ebert MPA, Chan ATC, Sung JJ*. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase l1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 2008; 48: 508-518. (*corresponding authors). 

9. Jin HC, Wang X, Ying JM, Wong AHY, Cui Y, Srivastava G, Shen ZY, Li EM, Zhang Q, Jin J, Kupzig S, Chan ATC, Cullen PJ, Tao Q. Epigenetic silencing of a ca2+-regulated ras gtpase-activating protein rasal defines a new mechanism of ras activation in human cancers. Proceedings of the National Academy of Sciences of USA 2007; 104: 12353-12358.

10. Chan ATC, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TWT, Johnson PJ, Ambinder RF. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. Journal of Clinical Oncology 2004; 22: 1373-1381. (# co-first author)